EVOLUTION OF COST STRUCTURES IN RHEUMATOID ARTHRITIS OVER THE PAST DECADE

Dörte Huscher,1,2 Thomas Mittendorf,3 Ulrich von Hinüber,4 Ina Kött,5 Guido Hoese,6 Andrea Pfäfflin,1 Sascha Bischoff,1 Angela Zink,1,2 for the German Collaborative Arthritis Centres

ABSTRACT

Objective To estimate the changes in direct and indirect costs induced by patients with rheumatoid arthritis (RA) in German rheumatology, between 2002 and 2011. To examine the impact of functional status on various cost domains. To compare the direct costs incurred by patients at working age (18–64 years) to patients at an age of retirement (≥65 years).

Methods We analysed data from the National Database of the German Collaborative Arthritis Centres with about 3400 patients each year. Costs were calculated using fixed prices as well as annually updated cost factors. Indirect costs were calculated using the human capital as well as the friction cost approaches.

Results There was a considerable increase in direct costs: from €4914 to €8206 in patients aged 18–64, and from €4100 to €6221 in those aged ≥65, attributable to increasing prescription of biologic agents (18–64 years from 5.6% to 31.2%, ≥65 years from 2.8% to 19.2%). This was accompanied by decreasing inpatient treatment expenses and indirect costs due to sick leave and work disability. The total growth of cost, on average, was €2437–2981 for patients at working age, and €2121 for patients at retirement age.

Conclusions The increase in treatment costs for RA over the last decade was associated with lower hospitalisation rates, better functional status and a lower incidence of work disability, offsetting a large proportion of risen drug costs. Since the rise in drug costs has manifested a plateau from 2009 onwards, no relevant further increase in total costs for patients with RA treated in German rheumatology is expected.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic inflammatory disease with a prevalence around 0.8 (range: 0.3–1.0) per 100 adults, and a peak in onset of disease between 55 years and 64 years of age.1-11 It has a high societal impact due to treatment requirements and losses in productivity. Cost-of-illness studies in Europe and Northern America estimated €4000–6000 for healthcare expenditures per patient and year.4-6 In a representative US household survey from 2008, the median annual healthcare expenditures for RA were US$4677 compared with US$1229 in a non-RA control group. Adjusted for differences in patient characteristics and comorbidities, incremental costs for RA were US $2085.4 In German rheumatology, treatment costs in 2002 were €4737 per patient and year.7

The growing use of biologic agents in daily rheumatological practice has led to a 3-fold to 6-fold increase in direct costs in various European countries.6-9 The changes in treatment patterns have been accompanied by a decrease in mean disease activity (DAS28), in hospitalisation, sick leave and work disability.10 Significant reductions in hospitalisation, outpatient physician care, nurse visits and physiotherapy were observed in Sweden between 2001 and 2010 in RA patients relative to the general population.11 A systematic review of 19 studies showed positive effects of biological agents on absenteeism and presenteeism.12 Since long-standing high disease activity, poor functional status and comorbidity are the main cost drivers in RA,13 14 the objective of this study was to analyse how recent changes in treatment and outcomes are reflected in resource utilisation and societal cost.

In Germany, biologic therapies for the treatment of RA are almost exclusively prescribed by rheumatologists. The National Database of the Collaborative Arthritis Centres (NDB), monitoring routine care in rheumatology since 1993, gives a structured insight to patients in need of these therapies. We analysed annual cross-sectional data from 2002 to 2011 to evaluate resource use and indirect cost components since the introduction of biologic therapies.

PATIENTS AND METHODS

Database We used data from outpatients fulfilling the 1987 American College of Rheumatology (ACR) criteria for RA15 who were enrolled in the NDB between 2002 and 2011. Consecutive patients seen in the participating clinics or practices were recorded once per year, either as new or as follow-up cases. Data monitoring, as well as checks for completeness and plausibility, were performed centrally. Of the 18 participating centres which can be considered representative of German rheumatology,10 four outpatient clinics and four rheumatologic practices continuously reported over the entire decade. Their data were included in the analysis. Physicians documented symptom onset, diagnosis, comorbid conditions, drug prescriptions, non-medicinal treatment (eg, physiotherapy), and the disease activity score based on 28 joints (DAS28-ESR). Patients reported the incidence and duration of hospitalisation, inpatient and outpatient rehabilitation, sick leave, retirement status including permanent work disability, and the number of physician visits. Patient-reported indicators of

To cite: Huscher D, Mittendorf T, von Hinüber U, et al. Ann Rheum Dis 2015;74:738–745.
quality of life were pain, fatigue and global health (on numerical rating scales from 0 to 10 with 10 being the poorest value) and functional status, using the Hannover Functional Status Questionnaire (FFbH). This 18-item scale with scores ranging from 0 to 100 (100=full function) can be transformed into Health Assessment Questionnaire (HAQ) values. We report the HAQ values in the following. The NDB received study approval from the ethics committee of the Charité Universitätsmedizin Berlin (EA1/196/06).

Cost components
When calculating the development of direct costs over time, two different approaches can be taken: resource utilisation cost can be calculated with fixed prices, taken from the first or the last observed year; alternatively, actual costs or prices from each respective year can be applied to reflect changes in pricing. We followed both approaches in figure 1 to visualise the differences. In all analyses we used current prices.

Direct costs in the context of this paper are defined as expenses from the perspective of the statutory health insurance. Around 90% of the German population is covered under this health insurance system, with almost full coverage of all health-care services, leaving only minimal copayments for patients.

In 2005, the documentation routine for disease-modifying anti-rheumatic drugs (DMARD) during the past 12 months was changed from a binary yes/no format to recording also start and stop dates, as well as dosages. We, therefore, imputed information on dosing and duration for DMARDs and glucocorticoids (GC) for 2002–2004 with the median values from the following years. Drug costs for DMARDs and GCs were calculated based on official prices for each individual year. Costs do not include the costs of administration.

For other concomitant drug therapies, such as non-selective NSAIDs, COX-2 inhibitors or antiosteoporotic drugs, information was available only in a yes/no format. Allowing for treatment start during the year and assuming a continuous intake due to the chronic disease thereafter, an average intake of 9 months with average dosages was used for calculation.

Patients reported on non-drug therapies, including physiotherapy, occupational therapy, and patient education, which they had received during the past 12 months through 2004. From 2005 onwards, this data was retrieved from the physician.

Imaging included X-rays of the hands, feet and spine, MRI, CT, sonography of the joints and osteodensitometry.

The average daily cost of inpatient rehabilitation was based on the annual statistics of the German Pension Insurance Funds. The hospitalisation costs were retrieved from the online database of the costs distribution of hospitals of the Federal Statistical Office.

In line with current health economic guidelines, the cost for a day of sick leave or work disability was calculated as the gross income from dependent work divided by the number of persons employed in dependent work, which resulted in €95–99 per day. We have restricted considerations to costs due to absenteeism, since presenteeism and occupational changes could not be estimated with our data. However, capturing the number of absent days is relatively straightforward and uncontroversial, while measurement of presenteeism and unpaid work still lacks a clear measurement methodology.

To evaluate indirect costs, a human capital (HCA), and also a friction cost approach (FCA) were used when calculating the

Figure 1  Cost development of direct and total costs with current prices (solid line), with fixed prices of 2002 (dashed line), and with fixed prices of 2011 (dotted line) for patients aged 18–64 years.
cost of disability pensions. The HCA assumes that an individual resigning from employment due to permanent work disability will not be replaced until the regular retirement age. The FCA takes into account that an early retired employee is replaced within a certain period,\textsuperscript{22, 25} in Germany 60–69 days in that decade (see online supplement S1).

The average annual costs were calculated for patients at working age (18–64 years), and for those in retirement age (≥65 years). Furthermore, costs were compared in subgroups stratified by functional capacity.

**RESULTS**

Between 2902 and 4020 adult patients with RA could be included in the analyses for the years 2002–2011 (table 1). On average, patients were 62 years old with median disease duration of 9 years. The mean disease activity score (DAS28-erythrocyte sedimentation rate (ESR)) decreased from 3.9 to 3.5 over the course of the observation. This is in line with an increase of the proportion of patients with a low disease activity (DAS28<3.2), from 35% in 2002 to 46% in 2011. Approximately half the patients were at working age with an average age of 52 years in that subgroup. The proportion of gainfully employed patients rose from 39% in 2002 to 53% in 2011. The proportion of patients on disability pension decreased from 24.5% to 20.6%. Despite the rising participation in the workforce, the proportion of patients with periods of sick leave during the past 12 months remained stable with about one-third of those gainfully employed, and the cumulative duration of sick leave episodes decreased from 60 days to 47 days for those with any disease absence. On average, the subpopulation in retirement was 73 years of age. There was no relevant difference in patient-reported outcomes or disease activity between the younger and the older groups.

**Use of healthcare**

Healthcare usage, which comprises physician visits, medications, non-drug treatments and hospitalisation as well as inpatient rehabilitation, changed considerably between 2002 and 2011 (table 2). In the entire patient population, the proportion of patients being prescribed biologic DMARDs increased from 4% in 2002 to 25% in 2011, with 31% in the younger and 19% in the older population in 2011. Inpatient treatments decreased in frequency and duration, with a more pronounced decline in duration in the older group, and in both groups higher shortening compared to the age-matched and sex-matched general population. Imaging techniques were applied with a decreasing frequency, which can be attributed mainly to an 18% decline in X-rays of hands and feet.

**Cost development**

During the analysed decade, overall direct cost of patients aged 18–64 years increased by 3292e (+67%) (figure 1). When applying fixed prices of 2002, the rise is somewhat lower (€2951, +60%). It is the lowest when using fixed prices of 2011 (€2352, +45%). Comparing total costs between 2002 and 2011, the increase is €2981 (+36%) with the FCA, and €2437 (+16%) when using the HCA. With fixed prices from 2002, this is reduced to €2448 (+29%) for FCA and €1481 (+10%) for HCA. Applying fixed prices of 2011, the total cost increase is the lowest with €2015 (+22%) for FCA, and €983 (+6%) for HCA, respectively.

In agreement with changing prescription patterns, costs for drug treatment increased, regardless of whether patients were at working age or retired (table 3). The increase in cost for biologic DMARDs was €3598 for younger patients, and €2265 for older patients. In the same period, the average cost for synthetic DMARDs decreased by €54 and €19, respectively. Costs for other antirheumatic drugs, including steroids, non-selective and selective NSAIDs, as well as osteoporosis prophylaxis or treatment, increased by €23–35.

The increasing drug costs were accompanied by decreasing costs for inpatient treatment, with reductions of €299 for a younger patient, and €429 for a retired patient. For younger patients, two-thirds of these savings were generated by fewer treatments in acute care hospitals, and one-third by less inpatient rehabilitation. For older patients, three-quarters of the cost savings were attributable to treatment in acute care hospitals, and one-quarter to rehabilitation. Other costs remained roughly the same. In summary, between 2002 and 2011, total direct costs increased by approximately €3292 for a patient at working age, and €2121 for a retired patient. Changes in cost shares for direct costs are illustrated in online supplement S2.

For patients at working age, the indirect costs of sick leave and permanent work disability form an important part of a patient’s average annual costs from a societal perspective. Sick leave accounted for approximately €1700 per patient in 2002, and decreased to €1530 in 2011 (table 3, upper part). The major indirect cost component is permanent work disability. When using the FCA, the share of permanent work disability was €1680 in 2002, decreasing to €1550 in 2011; when using the HCA, costs decreased from €8902 to €8229. In summary, total indirect cost decreased by €310 (FCA) and €855 (HCA).

Accordingly, the overall total annual costs increased by approximately €2981 with the FCA, or €2437 with the HCA, for patients at working age with RA. Retired patients had an increase in annual costs of approximately €2121.

By analysing a subsample of patients with disease duration 2–10 years, we reduced the variability of proportions of patients with early or very long-standing disease between the years (see online supplement S3). For the group aged 18–64 years, total costs calculated with the HCA did not show a systematic increase or decrease over the past decade, whereas for retired patients, total costs increased by €753.

**Cost development by functional capacity**

Since we had seen an overall shift towards better functional capacity, we investigated if costs changed within strata of functional capacity. For patients at working age (figure 2), the direct costs increased in patients with poor function (HAQ>2–3) from €9374 to €11376, in those with moderate disability (HAQ>1–2), from €5498 to €11109, in patients with mild disability (HAQ>0.5–1) from €3373 to €6930, and in those with good function (HAQ<0.5) from €2514 to €4473. By contrast, using HCA, indirect costs were lower in 2011 than in 2002 for patients with mild disability (€5842 compared to €5393), with good function (€2217 compared to €1137), and with severe disability (€29133 compared to €26789). However, there was an increase in those with moderate disability (€14375 to €15026). When applying the FCA, a stronger decline was seen in the group with severe disability (−€3932), and nearly no change in patients with good and moderate functional capacity (−€338, −€94). Regarding total costs, a considerable increase was seen in the group with moderate disability (+€6063 FCA and +€6262 HCA), while there were smaller increases in the two better groups (FCA/HCA: +€3263/+€2908 mild disability, +€1621/+€879 good function).
and a decrease in patients with severe disability (FCA/HCA: −€1930.0/−€343).

Only direct costs contribute to the cost calculation for retired patients. Most changes were induced by drug costs, correlating with the level of disability: the increase was €945 in the group with good functional capacity, €1621 in patients with mild, €2344 with moderate, and €4185 with severe functional disability (figure 3). Inpatient treatment, including hospitalisation and inpatient rehabilitation, led to a reduction in costs of €1382 between 2002 and 2011 for patients with severe disability, and €741 for patients with moderate disability. Other treatments, including physiotherapy, imaging, joint replacement surgery and physician visits, remained vastly stable in the two better groups and increased in those with moderate and severe disability (+€403, +€545). In total, the average annual costs rose by €3347 for patients with severe disability, by €2206 with moderate disability, and by €2204 with mild disability, and by €1114 for patients with good functional capacity.

Huscher D, Ann Rheum Dis 2015;74:738–745. doi:10.1136/annrheumdis-2013-204311 on 9 January 2014. Downloaded from http://ard.bmj.com/ Ann Rheum Dis: first published as 10.1136/annrheumdis-2013-204311 on June 19, 2022 by guest. Protected by copyright.

## Table 1 Patient characteristics of cases analysed from 2002 to 2011

| Year | Cases (n) | Male (%) | Age (mean±SD) | Disease duration (median) | DAS28-ESR (mean±SD) | Low activity, DAS28-ESR<3.2 (%) | Poor global health* (%) | Severe pain* (%) | Function (%) |
|------|-----------|----------|---------------|---------------------------|---------------------|-----------------------------|-------------------------|----------------|-------------|
| 2002 | 3600      | 20.9     | 61.2±12.4     | 8.0                       | 3.9±1.5             | 34.6                     | 24.3                    | 26.3           | 13.2        |
| 2003 | 3857      | 20.7     | 61.6±12.4     | 8.2                       | 3.8±1.4             | 37.6                     | 24.8                    | 26.5           | 22.2        |
| 2004 | 4020      | 21.2     | 61.9±12.4     | 8.2                       | 3.6±1.4             | 40.4                     | 24.9                    | 26.6           | 24.8        |
| 2005 | 2902      | 23.4     | 61.0±12.8     | 8.2                       | 3.4±1.1             | 42.7                     | 21.7                    | 25.1           | 23.6        |
| 2006 | 3172      | 24.3     | 61.7±12.9     | 8.7                       | 3.1±1.2             | 46.5                     | 20.7                    | 24.3           | 24.8        |
| 2007 | 3301      | 24.3     | 62.3±12.9     | 9.2                       | 3.4±1.3             | 49.1                     | 21.9                    | 25.1           | 25.2        |
| 2008 | 3108      | 25.1     | 62.5±12.9     | 9.0                       | 3.5±1.4             | 47.3                     | 21.6                    | 24.3           | 24.8        |
| 2009 | 2958      | 24.8     | 63.0±13.1     | 9.7                       | 3.4±1.3             | 48.4                     | 21.9                    | 24.9           | 25.0        |
| 2010 | 3420      | 25.3     | 63.6±13.1     | 10.2                      | 3.5±1.3             | 46.5                     | 21.9                    | 24.8           | 25.0        |
| 2011 | 3237      | 10.3     | 63.1±13.1     | 10.3                      | 3.5±1.3             | 46.3                     | 21.9                    | 24.8           | 25.0        |

* A score of 7–10 on a numerical rating scale from 0 to 10.
Clinical and epidemiological research

Table 2  Healthcare use from 2002 to 2011

| All patients | 2002       | 2003       | 2004       | 2005       | 2006       | 2007       | 2008       | 2009       | 2010       | 2011       |
|--------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Any DMARDs (%) | 86.3       | 84.9       | 87.3       | 87.1       | 80.8       | 84.5       | 84.4       | 85.5       | 86.0       | 85.8       |
| Synthetic DMARDs (%) | 84.0       | 81.1       | 82.4       | 79.7       | 72.6       | 77.8       | 77.0       | 76.5       | 77.9       | 76.9       |
| Biologics (%) | 4.4        | 8.2        | 9.6        | 14.0       | 16.8       | 16.2       | 19.4       | 23.4       | 23.9       | 25.2       |
| Other antirheumatic drugs (%) | 86.3       | 87.1       | 85.2       | 96.7       | 96.7       | 95.4       | 96.4       | 95.1       | 91.2       | 84.1       |
| Hospitalisation (%) | 19.6       | 17.2       | 17.6       | 16.9       | 16.2       | 16.8       | 18.2       | 16.7       | 16.9       | 16.3       |
| Duration in days (mean±SD) | 20.8±17.7  | 21.1±15.4  | 20.5±20.7  | 18.3±22.8  | 15.3±15.5  | 16.2±14.0  | 16.1±15.0  | 14.3±8.4   | 14.7±9.9   | 13.5±8.0   |
| Rehabilitation (%) | 12.9       | 10.8       | 9.7        | 10.4       | 9.5        | 12.4       | 12.1       | 11.9       | 24.5       | 11.3       |
| Duration in weeks (mean±SD*) | 3.6±1.2    | 3.8±3.1    | 3.6±1.8    | 3.5±0.2    | 3.6±0.2    | 3.5±0.2    | 3.5±0.2    | 3.5±1.8    | 3.8±2.5    | 3.3±1.7    |
| Physiotherapy (%) | 51.2       | 49.5       | 48.4       | 45.9       | 45.9       | 30.6       | 22.0       | 33.4       | 42.6       | 46.2       |
| Joint replacement surgery (%) | 2.3        | 2.2        | 2.1        | 3.5        | 3.5        | 2.5        | 1.9        | 3.5        | 3.2        | 3.5        |
| Imaging (%) | 85.1       | 82.7       | 82.5       | 83.0       | 69.9       | 75.8       | 67.3       | 71.3       | 72.4       | 72.5       |

| Age 18–64 years |  |  |  |  |  |  |  |  |  |  |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Any DMARDs (%) | 89.0           | 86.3           | 88.5           | 88.3           | 81.8           | 85.7           | 84.3           | 87.3           | 88.0           | 86.9           |
| Synthetic DMARDs (%) | 86.5           | 81.7           | 82.7           | 78.6           | 71.6           | 77.4           | 75.5           | 77.5           | 78.8           | 76.6           |
| Biologics (%) | 5.6            | 10.0           | 11.8           | 18.1           | 21.3           | 20.9           | 24.2           | 29.4           | 31.6           | 31.2           |
| Other antirheumatic drugs (%) | 85.4           | 85.1           | 83.0           | 95.8           | 95.8           | 93.8           | 95.2           | 93.1           | 89.8           | 79.7           |
| Hospitalisation (%) | 21.6           | 18.4           | 19.4           | 17.0           | 16.1           | 16.1           | 18.7           | 18.0           | 17.0           | 16.9           |
| Duration in days (mean±SD) | 18.9±15.0      | 19.2±13.6      | 19.4±21.1      | 15.5±13.2      | 14.4±11.2      | 16.2±17.0      | 16.4±18.2      | 12.9±7.7       | 14.1±9.1       | 13.7±9.2       |

| Mean duration of hospitalisation in days | 9.2            | 8.8            | 8.6            | 8.5            | 8.3            | 8.1            | 8.0            | 7.9            | 7.7            |
|----------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Age ≥65 years |  |  |  |  |  |  |  |  |  |  |
| Any DMARDs (%) | 82.5           | 83.1           | 85.9           | 85.7           | 79.6           | 83.3           | 84.6           | 83.8           | 84.3           | 84.8           |
| Synthetic DMARDs (%) | 80.6           | 80.3           | 82.1           | 81.1           | 73.7           | 78.2           | 78.5           | 75.7           | 77.2           | 77.1           |
| Biologics (%) | 2.8            | 6.0            | 7.0            | 9.0            | 11.7           | 11.7           | 14.7           | 18.0           | 17.5           | 19.2           |
| Other antirheumatic drugs (%) | 87.5           | 89.6           | 87.9           | 97.4           | 97.4           | 96.9           | 97.4           | 96.8           | 93.2           | 88.5           |
| Hospitalisation (%) | 16.8           | 15.5           | 15.4           | 16.7           | 16.3           | 17.6           | 17.6           | 15.4           | 16.8           | 15.7           |
| Duration in days (mean±SD) | 24.6±21.9      | 24.1±17.6      | 22.3±20.2      | 21.9±31.3      | 16.3±19.3      | 16.1±9.9       | 15.8±9.9       | 15.9±8.9       | 15.2±10.6      | 13.2±6.2       |

| Mean duration of hospitalisation in days | 11.4           | 10.8           | 10.4           | 10.3           | 10.0           | 9.9            | 9.6            | 9.4            | 9.0            |
|----------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|

*The duration of inpatient rehabilitation was not collected from 2005–2008; this duration was imputed by the mean duration from 2000 to 2004, stratified for function (FFbH). Consequently, we observed low SDs.

DMARD, disease modifying antirheumatic drugs.

Italic font indicates data that are not from our data source but from other sources for comparison.

DISCUSSION

There was a continuous increase in the average annual costs for patients with RA treated by German rheumatologists between 2002 and 2011, driven by the growing use of biologic agents. However, the increase was partly offset by decreasing costs for inpatient treatment, sick leave and work disability. Improvements in the employment situation seen in our data were similar to the population trend.

Our study has included direct and indirect costs only, not considering intangible costs related to quality of life. Constant improvements in physical function, pain, disease activity or global health over time suggest that a full economic evaluation including quality-adjusted life-year (QALY) considerations could further explore the trade-off between rising costs and improvements in quality of life, though these intangible costs are already partly reflected by savings in indirect cost domains.24

When taking disability into account, the doubled direct costs in patients with moderate or mild disability were not fully reflected in the total cost due to a shift in the patient case mix over time. For instance, in 2011, 22% of the patients were in a good functional status, the group with the lowest costs, compared to 15% in 2002.

The figures in our study correspond well with data from other Western European countries and Northern America: in a systematic review of 26 studies published up to 2007, Franke et al4 found a mean of €4170 annual healthcare costs for RA (IQR: 2756–4561). This is in line with our data for the first years of observation, while for the later years not covered by the review, we found higher direct costs.

The direct costs strongly depend on the prizes for drugs. In Norway, average annual drug costs in RA patients were €2249...
in a register with 16% prescription of biologic DMARDs, based upon prizes from 2010.6 In 2007, when we also had 16% biologics, our average annual drug costs were €3756. Boonen and Severens26 reported that for paid productivity loss the weighted mean sick leave costs were €2770 per patient, and productivity costs were €8452 using the HCA, and €1441 using the FCA. Our costs are lower for sick leave (€1707 in 2002 and €1525 in 2011) and comparable for permanent work disability. In a Swedish study,27 for inpatients aged 19–64 years, costs associated with sick leave and disability pension attributable to RA were €9000 in 2007, which closely corresponds to our indirect costs in 2007 of €9213 with the HCA.

The study has strengths and limitations: A strength is that we were able to observe changes for cost components in large patient samples gathered within the same study and in the same rheumatological units over 10 years. Clinical, patient-derived as well as resource-utilisation data were available. A limitation is that we probably underestimated 12-months-related components due to memory bias but, more importantly, overestimated drug costs: We had to use the published price list not accounting for discount contracts between health insurances and pharmaceutical companies, as each insurance fund has separate, confidential contracts. Individual discount rates can be up to 30%. Compared to German rheumatology in general, we overestimated the cost for biologic agents, since 50% of our units were hospitals which had higher prescriptions of biologics in our data (29% compared to 16% in practices in 2011), whereas 81% of German rheumatologists work in private practices.28 According to a population survey, 64% of RA patients in Germany were in rheumatological care in 2008.29 Since biologic agents are prescribed nearly exclusively by rheumatologists, when generalising to all RA patients, the costs for biologic agents per patient, therefore, have to be reduced by about one-third.

In summary, our data show that despite considerably increased drug costs, the overall costs of RA in patients treated by German rheumatologists did not change substantially. This might have been even more pronounced if we had been able to...
Figure 2  Comparison of the average annual costs in 2002 and 2011 for patients aged 18–64 years by functional capacity; calculated with current prices. HCA, human capital approach; FCA, friction cost approach.

Figure 3  Comparison of the average annual direct costs in 2002 and 2011 of patients aged ≥65 years by functional capacity; calculated with current prices (other treatment costs include physician visits, joint replacement surgery, physiotherapy, and imaging).
subtract price discounts. The data also show that the rise in drug costs driven by biologic agents has been at a plateau since 2009. This is supported by preliminary analyses of our database for 2012, which reveal prescription rates of biologic agents at the same level as 2011 (data not shown). Given the trend to earlier treatment initiation, improved treatment strategies with conventional DMARDs, including triple therapy, and overall better outcomes, we do not expect further large cost increases for the treatment of RA in Germany in the next few years.

Acknowledgements The authors acknowledge the invaluable contributions and the enthusiasm of all participating consultant rheumatologists who contributed data of their patients with inflammatory rheumatic diseases to the National Database since 1993. In particular, the authors would like to acknowledge the significant contributions of R Alten (Berlin), M Aringer (Dresden), M Backhaus (Berlin), H Burkhardt (Frankfurt/Main), R de la Camp (Erlangen), T Edler (Jena), K Fischer (Greifswald), K Karberg (Berlin), A Krause (Berlin), W Ochs (Bayreuth), Ht Peter (Freiburg), J Richter (Düsseldorf), S Spätling-Mestekemper (München) and S Wassenberg (Ratingen).

Contributors Conception and design, analysis and interpretation of data: DH, TM, SB, AP, AZ. Acquisition of data: UvH, IK, GH. Drafting the article: DH, TM, AZ. Revising it critically for important intellectual content: UvH, IK, GH, SB, AP. Final approval of the version published: DH, TM, UvH, IK, GH, SB, AP, AZ.

Funding The Federal Ministry of Research and Education funded the National Database from 1999 to 2007 (grant 01GI/9944/3). Since 2007, the database has been funded through unconditional grants from the German Collaborative Arthritis Centres and a consortium of 11 pharmaceutical companies. The principal investigators and their team had full academic freedom in study design and conduct, data analysis and publication of results.

Competing interests None.

Patient consent Obtained.

Ethics approval Ethics committee of the Charité Universitätsmedizin Berlin.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement This dataset is exclusively accessible by the Epidemiology Unit, German Data sharing statement Patient consent Competing interests None.

REFERENCES

1 Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002;41:793–800.
2 Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009;11:229.
3 Guillemín F, Sarau A, Guggenbuhl P, et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis 2005;64:1247–30.
4 Franke LC, Ament AJ, van de Laar MA, et al. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27:S118–23.
5 Kawskar AA, Jacobsen SJ, Levy GD, et al. Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care Res (Hoboken) 2012;64:1649–56.
6 Kwanmee MK, Lie E, Kvien TK, et al. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology (Oxford) 2012;51:1618–27.